^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NK cell stimulant

    Related drugs:
    2d
    Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2030 --> Jul 2031 | Trial primary completion date: Dec 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    CIML NK
    3d
    A Phase I Clinical Study Evaluating the Safety and Tolerability of CEL001 Injection in the Treatment of Advanced Solid Tumors (ChiCTR2600116105)
    P1, N=10, Recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Guangzhou Celling Biological Technology Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600
    3d
    A Multicenter Phase I Clinical Study of CD19-Targeted CAR-NK Cell Therapy for Moderate to Severe Active Systemic Lupus Erythematosus in China. (ChiCTR2600116668)
    P1, N=36, Not yet recruiting, Peking Union Medical College Hospital; Ruitherapeutics Co., LTD
    New P1 trial
    |
    MET positive
    |
    KN5501
    8d
    Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer (clinicaltrials.gov)
    P1, N=10, Completed, Zhejiang Provincial People's Hospital | Trial completion date: Sep 2025 --> Dec 2025
    Trial completion date
    |
    CLDN18 (Claudin 18)
    |
    cyclophosphamide • fludarabine IV
    8d
    A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (clinicaltrials.gov)
    P1, N=15, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Feb 2027 --> Jan 2026 | Trial primary completion date: Feb 2027 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date • Minimal residual disease
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV
    12d
    KN5501 Cell Injection for Refractory SLE(CLEAR) (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Ruitherapeutics Co., LTD
    New P1 trial
    |
    KN5501
    14d
    Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    pomalidomide
    26d
    CALiPSO-1: A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Century Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=48 --> 6
    Enrollment closed • Enrollment change
    |
    CNTY-101
    28d
    NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University
    New P1 trial
    |
    EGFR L858R
    1m
    A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=50, Recruiting, Dana-Farber Cancer Institute | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • CIML NK
    1m
    Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors. (PubMed, Immunother Adv)
    Lastly, TCR-NKs are not activated when co-cultured with normal cells, displaying a safe profile. Combining the innate cytotoxicity of NKs with MAGE-A4-specific targeting of an affinity-enhanced TCR, results in a potent and safe cellular product representing a promising and novel therapeutic off-the-shelf paradigm for the treatment of many solid cancers.
    Preclinical • Journal
    |
    MAGEA4 (Melanoma antigen family A, 4)
    1m
    A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS (clinicaltrials.gov)
    P1, N=20, Completed, MiNK Therapeutics | Phase classification: P1/2 --> P1
    Phase classification
    |
    AgenT-797